MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

In a decision signed Monday, North Carolina federal judge Kenneth Bell granted Merck’s motion to dismiss the claims of ...

MSD has opened the doors of a $1 billion manufacturing facility at its site in Durham, North Carolina, that will be used to produce the bulk drug substance for its HPV vaccine Gardasil.

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

Drugmaker Merck, known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by the end of the year, a senior company executive said on Wednesday."By the end ...

Merck opens new, $1 billion, 225,000-sq ft facility dedicated to vaccine manufacturing at its Durham, North Carolina, site: Durham, North Carolina Wednesday, March 12, 2025, 09:00 ...

Merck & Co. (MSD outside the U.S. and Canada) has just unveiled a brand-new, cutting-edge vaccine manufacturing facility at ...

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

Their CryptoMap platform leverages immunopeptidomics, genomics, and a bioinformatics pipeline, allowing the identification of ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial evaluating ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

HYDERABAD, India, Feb 26 (Reuters) - Drugmaker Merck (MRK.N), opens new tab, known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by the end of the ...